A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF
申请人:Hinova Pharmaceuticals Inc.
公开号:EP3957633A1
公开(公告)日:2022-02-23
The present invention relates to a class of bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof, and specifically provides a compound of formula (I), or an isotopic compound thereof, or an optical isomer thereof, or a tautomer thereof, or a pharmacologically acceptable salt thereof, or a prodrug thereof, or a solvate thereof, wherein ARB is an androgen receptor recognition/binding part, L is a link part, and U is a ubiquitin protease recognition/binding part; and the three parts are connected by means of chemical bonds. The compound can perform the targeted degradation on androgen receptors in prostate cancer cells, and suppress the proliferation of the prostate cancer cells, and also show good metabolic stability and pharmacokinetic properties. The compound has good application prospect in the preparation of targeted chimeras for protein degradation of androgen receptors and in the preparation of drugs for treating the related diseases regulated by the androgen receptors.
本发明涉及一类用于靶向降解雄激素受体的双官能嵌合杂环化合物及其用途,具体提供了式(I)化合物,或其同位素化合物,或其光学异构体,或其同系物,或其药理学上可接受的盐,或其原药,或其溶媒,其中ARB为雄激素受体识别/结合部分,L为连接部分,U为泛素蛋白酶识别/结合部分;这三个部分通过化学键连接。该化合物能对前列腺癌细胞中的雄激素受体进行靶向降解,抑制前列腺癌细胞的增殖,并具有良好的代谢稳定性和药代动力学特性。该化合物在制备靶向降解雄激素受体蛋白的嵌合体和制备治疗受雄激素受体调控的相关疾病的药物方面具有良好的应用前景。